Effect of acute kidney injury on mortality and hospital stay in patient with severe acute pancreatitis by Zhou, Jiaojiao et al.
Or ig ina l Ar t ic le
Effect of acute kidney injury on mortality and hospital stay in
patient with severe acute pancreatitis
JIAOJIAO ZHOU,1 YI LI,2 YI TANG,1 FANG LIU,1 SHAOBIN YU,1 LING ZHANG,1 XIAOXI ZENG,1 YULIANG ZHAO1 and
PING FU1
1Division of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China; and 2Kidney Epidemiology and Cost
Center, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA
KEY WORDS:
Acute Kidney Injury Network, acute kidney
injury, intensive care unit, risk factors, severe
acute pancreatitis.
Correspondence:
Professor Ping Fu, Division of Nephrology, West
China Hospital of Sichuan University, Chengdu
610041, China. Email: fupinghx@163.com
Conflict of interest: None.
Accepted for publication 22 February 2015.
Accepted manuscript online 26 February 2015.
doi:10.1111/nep.12439
SUMMARY AT A GLANCE
In this retrospective study of AKI following
acute pancreatitis, the authors identify risk
factors associated with mortality. These
findings provide a basis for focussing on
high risk patients for future trials of
therapeutic interventions.
ABSTRACT
Aim: Severe acute pancreatitis (SAP) is believed to be a major risk
factor leading to acute kidney injury (AKI) among critically ill patients,
but little is known about SAP-induced AKI. We study the incidence of
AKI defined by the Acute Kidney Injury Network (AKIN) criteria and
the risk factors associated with outcomes among SAP-induced AKI
patients.
Method: We conducted a multicenter retrospective study of critically ill
SAP-induced AKI patients during the period August 2009 to June 2013. Data
on enrolled patients were retrieved from electronic records. Univariate and
multiple regression analyses were performed.
Results: Among a total of 414 SAP patients admitted to intensive care
units(ICU), 287 (69.3%) developed AKI during their ICU stay, with 16.7%,
18.4%, and 34.3% classified as AKI stage I,II, and III, respectively. SAP-
induced AKI patients experienced a significantly higher ICU mortality
than those without AKI. The risk factors associated with ICU mortality
among SAP-induced AKI patients included ACS (odds ratio (OR) 10.58),
RRT (OR 3.31), sepsis (OR 2.46), CTSI (OR 3.01), APACHE II score (OR
1.82), AKI III (OR 1.38), ICU-length-of-stay (OR 1.04), and multi-organ
failure.
Conclusions: The paper represents the first attempt to investigate the etiol-
ogy and epidemiology of AKI following SAP under the AKIN criteria among
critically ill patients. Several independent risk factors were found to be
associated with ICU mortality for AKI patients. The findings may pinpoint
crucial therapeutic measures for preventing AKI among a vulnerable popu-
lation and for more effective management of SAP-induced AKI to improve
the quality of intensive care.
Acute kidney injury (AKI) is any abrupt impairment (within
48 h) of renal function and structure from any cause and is
characterized by the rapid loss of the kidney’s excretory
function. It is typically diagnosed by the accumulation of end
products of nitrogen metabolism (urea and creatinine) or
decreased urine output, or both. Commonly associated with
high morbidity and mortality, AKI is often secondary to
extrarenal events and familiar multifactorial etiology.1,2
Severe acute pancreatitis (SAP), an acute abdominal disease
with unpredictable clinical courses, is an important precursor
of AKI and drastically increases the disease burden.3 For
example, SAP leads to an incidence of AKI as high as 54%
among critically ill patients.4 Previous literature has also
revealed a 10-fold increase in mortality among critically ill
SAP-induced AKI patients.5,6 However, SAP-induced AKI is
greatly understudied, as the clinical characteristics and
underlying processes of AKI coexisting with SAP are still
elusive. Moreover, there are few clinical studies on etiologies
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and outcomes of SAP-induced AKI, especially among those
receiving intensive care. Of particular interest is the fact that,
even in the Kidney Disease: Improving Global Outcomes
(KDIGO) summary reviewed by Kellum and Lameire, SAP
was not mentioned as a cause of AKI.7
Since 2005, the Acute Kidney Injury Network (AKIN) has
advocated several important changes in the AKI criteria. For
example, the time constraint of diagnosis for AKI was intro-
duced to ensure that the process was acute and representa-
tive of events within a clinically relevant time period, and the
use of RRT was added as a criterion for AKI III. Some studies
have indicated that the AKIN criteria could improve the
sensitivity of AKI diagnosis.8–14 However, to our knowledge,
only one study with 50 SAP-induced AKI patients applied
the AKIN criteria.4
To address the knowledge gap, we plan to use the AKIN
criteria to define and classify AKI following SAP onset and
describe the clinical characteristics and laboratory results in
intensive care. The paper describes the epidemiology of AKI
with SAP under the AKIN criteria. Leveraging a relatively
large cohort of critically ill patients, we aim to explore the
severity of illness by using various scoring systems, investi-
gate risk factors associated with the development of AKI, and
describe the overall prognosis of this cohort.
METHODS
Study protocol
This was a retrospective and multi-center analysis of a database
collected from a large cohort study of critically ill patients admitted
to five ICU centers due to SAP in the time period between August
2009 to June 2013. Requirement for approval by the local ethics
committee and the need for informed consent were waived because
the retrospective study required neither therapeutic or prophylactic
intervention nor contravention of privacy or confidentiality.
Study population
All patients who were over 18 years old and admitted to the ICU
with evidence of SAP were eligible. However, patients who were
treated with renal replacement therapy (RRT) within the past month
or were on dialysis at ICU admission and had received kidney trans-
plant were excluded.
Data collection
Patients’ age, sex, laboratory data, clinical details, including the
aetiology of SAP, AKIN classification, disease history, presence of
comorbidity, and partial treatment, were collected in the database.
The primary outcomes were documented as the ICU- length-of-stay
(ICU-LOS) and mortality in ICU. The predictive role of two general
severity of illness scoring systems (Acute Physiology and Chronic
Health Evaluation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) scores) and two disease-specific scoring systems
(Computed Tomography Severity Index (CTSI) and Ranson scores)
were calculated using the worst values obtained in the first 48 h after
admission to ICU. Partial treatments such as operations, RRT,
mechanical ventilation, vasopressor use and diuretics were consid-
ered. The highest number of failed organs involved (except kidney)
during the ICU stay was summarized and recorded as ‘maximum
number of associated failed organ systems’ for each patient.
Definition
In our study, AKI is defined as an absolute increase in serum
creatinine of greater than or equal to 0.3 mg/dL (≥26.4 μmol/L) and
a percentage increase in serum creatinine of greater than or equal to
50% (1.5-fold from baseline) within 48 h. We define the lowest
value of serum creatinine measured within 2 days prior to ICU
admission as the baseline creatinine value. If no serum creatinine
was available, we considered the first creatinine available within 2
days after ICU admission as the baseline serum creatinine values.
AKI is classified as AKI stage I, II, or III, according to the patient’s
level of serum creatinine (Table 1). As 6- and 12-hourly urine
volumes were largely missing in the database, we used creatinine to
define and classify AKI and compare it with subsequent values every
2 days until death or discharge from ICU. The highest AKI stage
during patients’ ICU stay defines the final AKI classification. SAP, as
proposed by Bradley, known as the Atlanta classification, is estab-
lished by either an APACHE II score >8, Ranson score >3, the
presence of more than one organ failure, or local complications.15
Sepsis was defined as the presence of positive blood cultures accom-
panied by systemic inflammatory response syndrome (SIRS).16,17 The
World Society for Abdominal Compartment Syndrome (WSACS), an
international multi-specialty consortium proposed that intra-
abdominal pressure (IAP) is defined as sustained or repeated
pathologic elevation of IAP ≥ 12 mmHg and ACS is defined as a
sustained IAP ≥ 20 mmHg that is associated with new organ dys-
function.18 The scoring system of CTSI, modified by Mortele et al. in
2004, includes pancreatic inflammation, pancreatic necrosis and
extrapancreatic complications.19 At 48 h post-admission, a Ranson
score of ≥3 defines severe pancreatitis.20 Organ system failures were
assessed according to the method proposed by Knaus and colleagues,
supplemented by a definition for gastrointestinal failure (failure to
tolerate enteral nutrition).21,22
Table 1 Classification system for acute kidney injury (AKI)
AKIN
stage
Serum creatinine criteria Urine output criteria
1 Increase in serum creatinine of more than
or equal to 0.3 mg/dL (≥26.4 μmol/L) or
increase to more than or equal to 150%
to 200% (1.5- to 2-fold) from baseline
Less than 0.5 mL/kg
per hour for more
than 6 h
2 Increase in serum creatinine to more
than 200% to 300% (>2- to 3-fold) from
baseline
Less than 0.5 mL/kg
per hour for more
than 12 h
3 Increase in serum creatinine to more
than300% (>3-fold) from baseline (or
serum creatinine of more than or equal
to 4.0 mg/dL ( ≥ 354 μmol/L) with an
acute increase of at least 0.5 mg/dL
(44 μmol/L))
Less than 0.3 mL/kg
per hour for 24 h or
anuria for 12 h
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Statistical analysis
In our descriptive analysis, continuous variables are described as
mean ± standard deviations (SD) and 95% confidence intervals (CI).
Categorical variables are presented as proportions. Student’s t-tests,
one-way ANOVA and Pearson χ2 tests are used in the univariate
analysis to evaluate statistical associations. Multiple logistic regres-
sion is utilized to identify independent predictors of ICU mortality,
based on which odds ratios (ORs) are calculated. Risk factors that are
found to be significant in univariate analyses are considered in the
multiple regression model. A two-sided P-value < 0.05 is considered
statistically significant. The analysis is conducted using SPSS 17.0
(SPSS, Chicago, IL, USA).
RESULTS
A total of 414 patients with confirmed diagnosis of SAP
during the period of August 2009 to June 2013 are included
in our analysis. There are 287 (69.3%) SAP-induced AKI
patients, among whom 24.0%, 26.5% and 49.5% are clas-
sified as AKI I, II, and III, respectively, according to the AKIN
criteria. The mean (±SD) age is 50.2 (15.2) years, 56.8% of
patients are male, and ICU-LOS is 22.6 (10.6) days. Overall
ICU mortality is 37.4% (155/414) and AKI is associated with
a significantly higher ICU mortality (44.9% versus 20.5%,
P < 0.001) when compared to SAP patients without AKI. The
major causes of SAP are gallstone disease (40.3%) and
alcohol abuse (38.9%). The primary disease history and
laboratory data of patients who entered the ICU are summa-
rized in Table 2. The principal systemic complications are
SIRS (54.1%), followed by ACS (53.4%), and acute lung
injury (ALI) (44.9%). The mean (±SD) APACHE II score is
17.0 (7.9); the SOFA score, 9.4 (5.1); the Ranson score, 6.2
(1.7); and CTSI, 6.2 (2.5). The mean (±SD) baseline serum
creatinine level was 365.2 (284.7) μmol/L. Other laboratory
data and partial treatment are also presented in Table 2.
Table 3 shows an increasing linear trend with percentages of
29.0% for AKI I, 39.5% for AKI II, and 56.6% for AKI III.
Figure 1 depicts serum creatinine level trend in non-AKI and
AKI groups during their ICU stay.
A comparison of the basic characteristics and laboratory
variables between SAP patients with and without AKI are
listed in Table 3. The proportions of chronic kidney disease
(CKD), sepsis, and ACS are significantly higher in the AKI
group than in the non-AKI group (P < 0.05). A number of
factors are associated with significant differences between
AKI I, II, and III patients in Table 3 (P < 0.05). Patients with
AKI are mostly older and have higher baseline serum
creatinine, blood urea nitrogen (BUN), Cystain-C, and
C-reactive protein (CRP) levels when compared with
patients without AKI (P < 0.05). However, there was no sig-
nificant difference between having AKI and not having AKI
in the aetiology, and also no significant difference among
AKI I, II, and III patients. Meanwhile, ICU-LOS was not a
significant risk factor and did not distinguish patients who
developed AKI and those who did not (Table 3).
Table 2 Baseline characteristics of study population
Age (years; mean ± SD) 50.2 ± 15.2
Gender, n (%)
Male 235 (56.8)
Female 179 (43.2)
AKI stage, n (%)
No-AKI 127 (30.7)
AKI I 69 (16.7)
AKI II 76 (18.4)
AKI III 142 (34.3)
ICU-LOS (days; mean ± SD) 22.6 ± 10.6
Aetiology, n (%)
Biliary 167 (40.3)
Alcohol 161 (38.9)
Other 86 (20.8)
Disease history, n (%)
Hypertension 94 (22.7)
Diabetes 48 (11.6)
Heart failure 80 (19.3)
Chronic liver disease 62 (15.0)
Malignancy 15 (3.6)
COPD 83 (20.0)
CKD 38 (9.2)
Comorbidity, n (%)
ALI 186 (44.9)
ARDS 164 (39.6)
ALF 22 (5.3)
SIRS 224 (54.1)
Sepsis 90 (21.7)
Hypoalbuminemia 138 (33.3)
ACS 221 (53.4)
Laboratory data, mean ± SD
HGB (g/L) 89.1 ± 16.3
Platelets (109/L) 160.0 ± 79.7
WBC (109/L) 14.3 ± 6.6
Baseline serum creatinine (μmol/L) 365.2 ± 284.7
BUN (mmol/L) 13.00 ± 5.8
UA (μmol/L) 421.4 ± 141.6
Cystain-C (mg/L) 1.8 ± 0.6
AST (IU/L) 467.2 ± 325.2
ALT (IU/L) 497.2 ± 304.1
Lac (mmol/L) 5.7 ± 2.6
LDH (IU/L) 1083.8 ± 980.9
Glucose (mmol/L) 14.0 ± 5.5
AMY (IU/L) 1024.80 ± 742.3
LPS (IU/L) 1163.28 ± 881.0
Ca (mmol/L) 1.7 ± 0.4
CRP (mg/L) 175.08 ± 74.19
Scoring systems, mean ± SD
APACHE II score 17.00 ± 7.9
SOFA score 9.4 ± 5.1
Ranson score 6.2 ± 1.7
CTSI 6.2 ± 2.5
Therapy requirements, n (%)
Operation 88 (21.3)
RRT 245 (59.2)
Mechanical Ventilation 28568.8)
Vasopressor use 157 (37.9)
Diuretic 120 (29.0)
ACS, abdominal compartment syndrome; AKI, acute kidney injury; ALF, acute
liver failure; ALI, acute lung injury; ALT, aspartate transaminase; AMY, amylase;
APACHE II, Acute Physiology and Chronic Health Evaluation scoring system
version II; ARDS, acute respiratory distress syndrome; AST, aspartate
aminotransferase; BUN, blood urea nitrogen; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CTSI,
Computed Tomography Severity Index; HGB, hemoglobin; ICU-LOS, intensive
care unit length of stay; Lac, lactic acid; LDH, lactic dehydrogenase; LPS,
lipase; RRT, renal replacement therapy; SIRS, systemic inflammatory response
syndrome; SOFA, Sequential Organ Failure Assessment; UA, uric acid; WBC,
white blood cell.
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We next performed a multiple logistic regression on these
287 SAP-induced AKI patients to identify the effect of the
independent risk factors on ICU mortality. Our univariate
analysis identified that ICU-LOS, AKIN stage, SIRS, sepsis,
hypoproteinaemia, ACS, ARDS, ALI, and maximum number
of associated organ failures were significant risk factors. The
APACHE II score and CTSI are higher in non-survivors
(Table 4). However, there are no significant differences in
age, CKD, Ranson and SOFA score (P > 0.05) between both
groups. The results of multivariate logistic regression analysis
are shown in Table 5. After adjustment for covariates, in SAP
patients with AKI, independent risk factors for mortality
included ACS (OR 10.58; 95% CI 5.98 to 18.72), renal
replacement therapy (RRT) (OR 3.31; 95%CI 1.77 to
6.19), sepsis (OR 2.46; 95% CI 1.10 to 4.01), Computed
Table 3 Clinical characteristics and laboratory data associated with acute kidney injury (AKI) and Non-AKI
Non-AKI AKI I AKI II AKI III P1 P2
n = 127 n = 69 n = 76 n = 142 AKI vs Non-AKI Among AKI I, II, III
Age, years 46.6 ± 14.8 53.2 ± 16.1 46.4 ± 14.2 48.8 ± 15.0 0.021 0.014
Gender (Female), n (%) 50 (39.4) 51 (73.9) 31 (40.8) 47 (33.1) 0.177 0.031
Mortality, n (%) 26 (20.5) 20 (29.0) 30 (39.5) 79 (55.6) <0.001 <0.001
Aetiology, n (%)
Biliary 57 (44.9) 37 (53.6) 24 (31.6) 49 (34.5) 0.210 0.362
Alcohol 48 (37.8) 34 (49.3) 34 (44.7) 45 (31.7) 0.761 0.526
Others 22 (17.3) 18 (26.1) 18 (23.7) 28 (19.4) 0.250 0.846
Disease history, n (%)
Hypertension 31 (24.4) 23 (33.3) 11 (14.5) 29 (20.4) 0.582 0.174
Diabetes 14 (11.0) 15 (21.7) 6 (7.9) 13 (9.2) 0.809 0.179
Heart failure 38 (29.9) 18 (26.1) 11 (14.5) 13 (9.2) <0.001 <0.001
Chronic liver disease 18 (14.2) 13 (18.8) 6 (7.9) 25 (17.6) 0.761 0.056
Malignancy 3 (2.4) 5 (7.2) 3 (3.9) 4 (2.8) 0.361 0.702
COPD 25 (19.7) 25 (36.2) 9 (11.8) 24 (16.9) 0.902 0.034
CKD 6 (4.7) 6 (8.7) 8 (10.5) 18 (12.7) 0.037 0.158
Sepsis 22 (17.3) 23 (33.3) 21 (27.6) 24 (16.9) <0.001 0.362
ACS 62 (48.8) 42 (60.1) 39 (51.3) 78 (54.9) <0.001 <0.001
ICU-LOS, days 22.4 ± 10.3 24.8 ± 15.8 22.6 ± 11.4 25.0 ± 12.5 0.074 0.218
Laboratory data, mean ± SD
HGB (g/L) 89.9 ± 16.2 90.7 ± 16.7 87.3 ± 16.3 88.1 ± 15.9 0.445 0.360
PLT (109/L) 165.6 ± 81.2 167.8 ± 79.9 156.2 ± 85.6 150.9 ± 73.9 0.346 0.303
WBC (109/L) 14.0 ± 6.4 14.3 ± 7.4 13.5 ± 5.8 15.2 ± 6.7 0.487 0.229
Baseline serum creatinine (μmol/L) 119.4 ± 95.7 185.9 ± 142.7 393.3 ± 198.9 734.5 ± 386.3 <0.001 <0.001
BUN (mmol/L) 11.5 ± 4.8 13.6 ± 6.3 12.8 ± 5.5 14.2 ± 6.4 <0.001 0.288
UA (μmol/L) 415.8 ± 124.8 406.1 ± 143.1 445.0 ± 123.5 423.8 ± 165.2 0.565 0.245
Cystain-C (mg/L) 1.6 ± 0.5 1.7 ± 0.5 1.8 ± 0.6 2.0 ± 0.6 <0.001 0.007
AST (IU/L) 449.4 ± 339.8 540.7 ± 420.8 719.0 ± 412.8 629.3 ± 415.0 <0.001 <0.001
ALT (IU/L) 465.2 ± 341.1 427.7 ± 306.1 716.5 ± 488.6 759.3 ± 403.1 <0.001 <0.001
Lac (mmol/L) 5.9 ± 2.5 5.6 ± 3.0 5.1 ± 2.4 5.9 ± 2.5 0.361 0.163
LDH (IU/L) 983.1 ± 674.6 1160.2 ± 720.5 1027.0 ± 597.5 1168.2 ± 641.5 0.165 0.639
Glucose (mmol/L) 13.8 ± 5.1 13.8 ± 5.8 11.1 ± 6.0 14.5 ± 5.5 0.485 0.641
AMY (IU/L) 877.6 ± 488.7 1052.1 ± 875.0 1112.1 ± 787.8 1118.5 ± 922.1 0.033 0.059
LPS (IU/L) 1053.4 ± 865.4 1108.6 ± 1580.8 1262.6 ± 733.0 1392.3 ± 865.5 0.042 0.063
Ca (mmol/L) 1.8 ± 0.4 1.6 ± 0.4 1.8 ± 0.4 1.7 ± 0.4 0.277 0.046
CRP (mg/L) 192.9 ± 82.3 177.4 ± 82.1 146.7 ± 55.6 172.5 ± 63.8 0.002 0.009
ACS, abdominal compartment syndrome; ALT, aspartate transaminase; AMY, amylase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; HGB, hemoglobin; Lac, lactic acid; LDH, lactic dehydrogenase; LPS, lipase;
UA, uric acid; WBC, white blood cell.
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Fig. 1 The trend of renal function change in non-acute kidney injury (AKI) and
AKI groups. ( ) Non-Akl, ( ) AKI I, ( ) AKI II, ( ) AKI III.
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Tomography Severity Index (CTSI) (OR 3.01; 95% CI 1.78 to
5.32), APACHE II score (OR 1.82; 95% CI 1.23 to 2.72), AKI
III (OR 1.38; 95% CI 1.19 to 1.77), ICU-LOS (OR 1.04; 95%
CI 1.01 to 1.07), and multi-organ failure (Table 5).
DISCUSSION
Despite significant progress in the management of patient
treatment, such as early enteral nutrition, decompression
surgery, and RRT, SAP remains a severe medical condition
with multi-organ failure and a poor clinical prognosis, espe-
cially in critically ill patients.23 We conducted a retrospective
analysis of ICU patients, validated the ability of the AKIN
criteria to evaluate the occurrence of AKI in SAP patients,
and assessed risk factors for ICU mortality.
Our results suggest that AKI patients experience a signifi-
cantly higher ICU mortality compared with those who never
develop AKI during intensive care (20.5% vs 44.9%,
P < 0.001), which is consistent with published reports.24,25
The mortality in the AKI III group is the highest at 55.6%
compared with the AKI I and II groups. Moreover, more
advanced AKIN classifications are associated with higher
rates of ICU mortality, in an approximately linear fashion.
Our analysis demonstrates that AKI is more common among
older patients and the incidence of ACS increases as the AKI
stage increases (Table 3). In our study, heart failure rate and
CRP level were higher in the non-AKI group than in the AKI
group. Both results were surprising, compared to many other
reports on AKI. Possible reasons include differences in the
populations characteristics studied, and different criteria in
the diagnosis of AKI, for example, RIFLE criteria or KDIGO
criteria. In addition, SAP is a dysregulated inflammatory
Table 4 Univariate analysis of risk on intensive care unit (ICU) mortality for
patients with acute kidney injury (AKI) following severe acute pancreatitis
(SAP)
Variables Non-survivors Survivors P-value
(n = 129) (n = 158)
Age, year 51.2 ± 15.2 48.4 ± 15.0 0.116
Gender (Female), n (%) 54 (41.9) 71 (44.9) 0.601
ICU-LOS, days 25.9 ± 15.7 20.8 ± 9.2 0.001
AKI stage, n (%)
AKI I 20 (15.5) 49 (31.0) <0.001
AKI II 30 (23.3) 46 (29.1) <0.001
AKI III 79 (61.2) 63 (39.9) <0.001
The etiology, n (%)
Biliary 48 (37.2) 62 (39.2) 0.653
Alcohol 49 (38.0) 64 (40.5) 0.436
Other 32 (24.8) 32 (20.3) 0.261
Disease history, n (%)
Hypertension 33 (25.6) 30 (19.0) 0.179
Diabetes 17 (13.2) 17 (10.8) 0.528
Heart failure 22 (17.1) 24 (15.2) 0.668
Chronic liver disease 19 (14.7) 25 (15.8) 0.798
Malignancy 5 (3.9) 7 (4.4) 0.815
COPD 30 (23.3) 28 (17.7) 0.245
CKD 12 (9.3) 20 (12.7) 0.369
Comorbidity, n (%)
ALI 58 (45.0) 51 (32.3) 0.028
ARDS 68 (52.7) 59 (37.3) 0.009
ALF 10 (7.8) 8 (5.1) 0.350
SIRS 76 (58.9) 68 (43.0) 0.007
Sepsis 33 (25.6) 25 (15.8) 0.031
Hypoproteinemia 53 (41.1) 39 (24.7) 0.003
ACS 88 (68.2) 71 (44.9) 0.012
Scoring systems, mean ± SD
APACHE II score 18.1 ± 8.7 15.2 ± 6.6 <0.001
SOFA score 9.8 ± 5.2 8.8 ± 4.9 0.089
Ranson score 6.3 ± 1.8 6.1 ± 1.9 0.067
CTSI 6.5 ± 2.7 5.7 ± 1.9 0.007
Maximum number of associated failed organ systems during ICU stay
(excluding AKI)
1 failed organ 21 23 <0.001
2 failed organs 36 43 <0.001
3 failed organs 82 48 <0.001
≥4 failed organs 24 10 <0.001
Therapy requirements, n (%)
Operation 29 (22.5) 22 (13.9) 0.059
RRT 89 (69.0) 64 (40.5) 0.011
Mechanical ventilation 106 (82.2) 77 (48.7) 0.004
Vasopressor use 51 (39.5) 50 (31.6) 0.164
Diuretic 30 (23.3) 47 (29.4) 0.362
ACS, abdominal compartment syndrome; ALF, acute liver failure; ALI, acute
lung injury; APACHE II, Acute Physiology and Chronic Health Evaluation scoring
system version II; ARDS, acute respiratory distress syndrome; CKD, chronic
kidney disease; COPD, chronic obstructive pulmonary disease; CTSI, com-
puted tomography Severity Index; RRT, renal replacement therapy; SIRS, sys-
temic inflammatory response syndrome; SOFA, Sequential Organ Failure
Assessment.
Table 5 Risk factors for intensive care unit (ICU) mortality according to multi-
variate logistic regression analysis
β P OR 95% confidence
interval
Lower Upper
ICU-LOS 0.04 0.03 1.04 1.01 1.07
AKI III 0.97 0.01 1.38 1.19 1.77
Sepsis 0.74 0.21 2.46 1.10 4.01
ACS 2.36 <0.001 10.58 5.98 18.72
CTSI 2.14 0.01 3.01 1.78 5.32
APACHE II score 1.35 0.04 1.82 1.23 2.72
Maximum number of associated failed organ systems during ICU stay
(excluding AKI)
2 1.48 <0.001 1.23 1.09 1.55
3 1.04 0.01 1.75 1.45 2.63
≥4 1.01 0.04 2.36 2.14 2.93
RRT 1.20 <0.001 3.31 1.77 6.19
AKI, acute kidney injury; ACS, Abdominal Compartment Syndrome; APACHE II,
Acute Physiology and Chronic Health Evaluation scoring system version II;
CTSI, computed tomography Severity Index; ICU-LOS, intensive care unit-
length-of-stay RRT, renal replacement therapy.
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response to infection and it can lead to multiple-organ dys-
function syndrome in the end. The CRP level cannot com-
pletely reflect systemic inflammation in critically ill patients.
Our analysis has identified several factors as predictors for
ICU mortality. ICU-LOS, AKI III (using AKI I as the reference
classification), sepsis, ACS, CTSI, APACHE II score, RRT, and
multiple failed organ systems (using one failed organ system
as the reference classification) are the primary and independ-
ent factors for mortality in this cohort. Patients with a history
of renal disease who develop SAP have a significant risk
factor for developing AKI, but it is not an independent prog-
nostic factor, in contradiction with some studies.5,24,26 Mean-
while, our conclusion that the type of treatment, except for
RRT, is not independently associated with ICU mortality also
contrasts with studies that focused on other types of
nephrology.12,27–29
Several studies have asserted that renal failure is always
one of the main drivers in multi-organ failure due to SAP.23,30
The main pathophysiology is initiated as an uncontrolled
systemic inflammatory process with ensuing hypovolaemia,
either from wide-spread vasodilation or fluid sequestration,
and reduced tissue perfusion, which ultimately causes organ
damage and failure, even multi-organ failure.24 We show
that multi-organ failure is an important prognostic factor in
SAP induced-AKI as reported previously.5,31,32
Sepsis is a highly prevalent syndrome characterized by a
whole-body inflammatory state and the presence of a known
or suspected infection that has severe consequences, includ-
ing multi-organ failure.10 Previous reports have suggested that
AKI is frequently considered to be a serious complication of
sepsis in ICU patients and that septic AKI effects an important
and independent increase in the risk for hospital death.10,27,33
In our study, the prevalence of sepsis as a complication of SAP
was 21.7%. AKI occurred in 75.6% (68/90) of all critically ill
patients with both SAP and sepsis. In multivariate logistic
regression analysis, the sepsis showed an ICU mortality odds
ratio of 2.46 (P < 0.001). The findings of our study confirm
and largely extend a previous investigation.34
There are several different scoring systems aimed at esti-
mating the prognosis of patients with SAP.20,35–38 The
APACHE II and the SOFA scores are general severity of
illness scoring systems that are positively correlated with SAP
severity and have good prognostic value.35,37,39 The Ranson
scores are the most commonly used and the CTSI has been
shown to have good predictive value.20,38 However, in our
original study, we find only that CTSI and APACHE II scores
were significant risk factors for AKI in patients with SAP, at
variance with previous studies. An adequately powered vali-
dation study is necessary to evaluate the role of the various
scores in the AKI cohort following SAP onset.
Limitations
There are, however, some limitations in our study. First, the
diagnosis of SAP was made partly at the discretion of indi-
vidual investigators. Second, due to lack of exact and com-
plete urine volumes, we had to resort to serum creatinine
levels obtained in the relevant period. As a result, we may
have underestimated patients who only fulfilled the AKI
criteria on urine output and, perhaps, underestimated the
incidence of AKI. Third, there is no cause-effect relationship
between ICU stay and development of AKI that can be
drawn in this cross-sectional study, but we have verified risk
factors that may be associated with AKI in the hospital or
ICU settings as in previous research. Finally, as no data on
long-term follow-up were available beyond the ICU dis-
charge, patients’ long-term mortality and renal conditions
remain unknown.
Conclusion
Few epidemiological studies have been conducted on the
SAP-induced AKI patients cohorts. The results of the present
research suggest that the AKIN criteria might offer sensitive
diagnostic measures among SAP patients. We have found
that ACS, RRT, sepsis, CTSI, APACHE II score, AKI III, ICU-
LOS, and multi-organ failure are significant risk factors asso-
ciated with high ICU mortality among the SAP-induced AKI
patients. Our findings have the potential to lead to effective
therapeutic measures to prevent and manage SAP-induced
AKI, with the ultimate goal of improving survival outcomes
among critically ill patients.
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